title: Plasma gelsolin is a marker and therapeutic agent in animal sepsis.
abstract: OBJECTIVE
  Plasma gelsolin is a circulating actin-binding protein that serves a protective role against tissue injuries. Depletion of plasma gelsolin in systemic inflammation may contribute to adverse outcomes. We examined the role of plasma gelsolin in animal models of sepsis.
  
  
  METHODS
  Animal and laboratory experiments.
  
  
  METHODS
  Academic research laboratory.
  
  
  METHODS
  Adult male mice.
  
  
  METHODS
  Mice subjected to endotoxin or cecal ligation and puncture (CLP) were treated with exogenous plasma gelsolin or placebo.
  
  
  RESULTS
  We document the depletion of plasma gelsolin (25-50% of normal) in murine models of sepsis associated with the presence of circulating actin within 6 hrs of septic challenge. Repletion of plasma gelsolin leads to solubilization of circulating actin aggregates and significantly reduces mortality in endotoxemic mice (survival rates were 88% in the gelsolin group vs. 0% in the saline group, p < .001) and in CLP-challenged mice (survival rates were 30% in the gelsolin group vs. 0% in the saline group, p = .001). Plasma gelsolin repletion also shifted the cytokine profile of endotoxemic mice toward anti-inflammatory (plasma interleukin-10 levels were 205 +/- 108 pg/mL in the gelsolin group vs. 39 +/- 29 pg/mL in the saline group, p = .02).
  
  
  CONCLUSIONS
  We propose that circulation of particulate actin is a marker for sepsis-induced cell injury, that plasma gelsolin has a crucial protective role in sepsis, and that gelsolin replacement represents a potential therapy for this common lethal condition.
authors.affiliation: Pulmonary and Critical Care Division Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: Po-Shun
authors.initials: PS
authors.lastname: Lee
authors.forename: Aaron B
authors.initials: AB
authors.lastname: Waxman
authors.forename: Kara L
authors.initials: KL
authors.lastname: Cotich
authors.forename: Su Wol
authors.initials: SW
authors.lastname: Chung
authors.forename: Mark A
authors.initials: MA
authors.lastname: Perrella
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Stossel
mesh_terms: D000199:Actins / Q000097:blood; D000818:Animals; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D019446:Endotoxemia / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality; D004926:Escherichia coli; D018260:Gelsolin / Q000097:blood* / Q000627:therapeutic use*; D008070:Lipopolysaccharides; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D010538:Peritonitis / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D012772:Shock, Septic / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D051197:Toll-Like Receptor 4 / Q000235:genetics
chemical_list: D000199:Actins; D016207:Cytokines; D018260:Gelsolin; D008070:Lipopolysaccharides; D051197:Toll-Like Receptor 4